A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis

• Status: Completed
• Trial end date: 2004-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Infliximab is safe and effective in the treatment of psoriatic arthritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Diagnosed psoriatic arthritis for >= 6 months

• active arthritis with >= 5 tender and 5 swollen joints

• active psoriasis

Exclusion Criteria:

• Have other inflammatory diseases, including but not limited to, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease

• Received any systemic immunosuppressives within 4 weeks prior to enrollment in the study